What recent returns signal about Revvity stock

Without a specific headline event setting the tone, Revvity (RVTY) has drawn investor attention through its recent performance, with the stock showing positive returns over the past week, month, and past 3 months.

Over the past week, Revvity is up about 1.2%, adding to an advance of roughly 10.9% over the past month and 12.1% over the past 3 months. For context, the stock’s 1 year total return sits near 13.5%, while the 3 year and 5 year total returns indicate declines over those longer periods.

At the last close of US$102.40, Revvity carries a market value of about US$11.3b. The company reports annual revenue of roughly US$2.9b and net income of about US$239.1m, with both metrics showing annual growth based on the data provided.

Revvity operates across its Diagnostics and Life Sciences segments, each contributing around US$1.45b in revenue. Diagnostics covers instruments, reagents, software, and services for early detection and infectious disease testing. Life Sciences supports genomic workflows, oncology, immunodiagnostics, and drug discovery tools.

For readers watching valuation metrics, the stock is flagged with an internal value score of 3 and an intrinsic discount measure of 24.3%. There is also an implied upside when compared with an external reference price of US$113.64, although that figure is only one of many datapoints investors may weigh.

That recent 1 month share price return of about 10.9% and 3 month gain of 12.1%, alongside a 1 year total shareholder return of 13.5% but weaker 3 and 5 year outcomes, suggests short term momentum is improving while longer term holders have yet to recoup earlier declines.

If Revvity’s recent move has you rethinking where growth in diagnostics and life sciences tools might lead next, it can be useful to compare it with specialist healthcare AI companies using the 40 healthcare AI stocks.

With Revvity trading at US$102.40 alongside an internal value score of 3, an intrinsic discount of 24.3% and a 10.9% gap to one external price target, is this a mispriced opportunity, or is the market already baking in future growth?

Most Popular Narrative: 9.9% Undervalued

Revvity's most followed narrative pegs fair value at about $113.64, compared with the last close of $102.40. This frames the recent share price strength in a valuation gap.

Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.

Want to see what sits behind that margin lift and valuation gap? Earnings, revenue and buyback assumptions combine into a tight, numbers driven roadmap.

Result: Fair Value of $113.64 (UNDERVALUED)

However, those assumptions can quickly be challenged if changes in China’s reimbursement continue to pressure diagnostics volumes or if academic and government funding remains weaker for longer.

Next Steps

If this combination of concerns and optimism seems finely balanced, review the same data promptly and form your own view with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Revvity has sharpened your focus, do not stop here, fresh opportunities across quality income, value, and lower risk stocks are only a few clicks away.

• Target resilient income by scanning companies that offer strong yields and robust balance sheets using the 10 dividend fortresses.
• Hunt for potential value gaps across the market with the 47 high quality undervalued stocks before other investors catch on.
• Prioritize stability by filtering for companies with stronger financial footing through the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.